81 related articles for article (PubMed ID: 25205401)
1. A subtraction tolerization method of immunization allowed for Wilms' tumor protein-1 (WT1) identification in melanoma and discovery of an antitumor peptide sequence.
Massaoka MH; Matsuo AL; Figueiredo CR; Girola N; Farias CF; Pasqualoto K; Travassos LR
J Immunol Methods; 2014 Dec; 414():11-9. PubMed ID: 25205401
[TBL] [Abstract][Full Text] [Related]
2. A novel cell-penetrating peptide derived from WT1 enhances p53 activity, induces cell senescence and displays antimelanoma activity in xeno- and syngeneic systems.
Massaoka MH; Matsuo AL; Figueiredo CR; Girola N; Faria CF; Azevedo RA; Travassos LR
FEBS Open Bio; 2014; 4():153-61. PubMed ID: 24490140
[TBL] [Abstract][Full Text] [Related]
3. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
4. Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor.
Rong Y; Cheng L; Ning H; Zou J; Zhang Y; Xu F; Liu L; Chang Z; Fu XY
Cancer Res; 2006 Aug; 66(16):8049-57. PubMed ID: 16912181
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus.
Morris JF; Madden SL; Tournay OE; Cook DM; Sukhatme VP; Rauscher FJ
Oncogene; 1991 Dec; 6(12):2339-48. PubMed ID: 1662794
[TBL] [Abstract][Full Text] [Related]
6. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
7. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.
Gaiger A; Reese V; Disis ML; Cheever MA
Blood; 2000 Aug; 96(4):1480-9. PubMed ID: 10942395
[TBL] [Abstract][Full Text] [Related]
8. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain.
Sakamoto Y; Yoshida M; Semba K; Hunter T
Oncogene; 1997 Oct; 15(17):2001-12. PubMed ID: 9366517
[TBL] [Abstract][Full Text] [Related]
10. Novel replication inhibitory function of the developmental regulator/transcription repressor protein WT1 encoded by the Wilms' tumor gene.
Anant S; Axenovich SA; Madden SL; Rauscher FJ; Subramanian KN
Oncogene; 1994 Nov; 9(11):3113-26. PubMed ID: 7936634
[TBL] [Abstract][Full Text] [Related]
11. Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice.
Babiarova K; Kutinova L; Zurkova K; Krystofova J; Brabcova E; Hainz P; Musil J; Nemeckova S
J Immunother; 2012 Jul; 35(6):478-87. PubMed ID: 22735806
[TBL] [Abstract][Full Text] [Related]
12. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
[TBL] [Abstract][Full Text] [Related]
13. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
16. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
17. Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain.
Deuel TF; Guan LS; Wang ZY
Biochem Biophys Res Commun; 1999 Jan; 254(1):192-6. PubMed ID: 9920756
[TBL] [Abstract][Full Text] [Related]
18. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
Iben S; Royer-Pokora B
Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
[TBL] [Abstract][Full Text] [Related]
19. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.
Haber DA; Buckler AJ
New Biol; 1992 Feb; 4(2):97-106. PubMed ID: 1313285
[TBL] [Abstract][Full Text] [Related]
20. Novel frame shift mutations ('A' deletion) observed in exon 9 of Wilms' tumor (WT1) gene in a patient reported with glomerulosclerosis.
Pasupuleti SK; Katari V; Lokanathan S; Uppu VP; Thummaginjala SS; Akkamgari RP; Ayapati T; Kottu R; Potukuchi VG
Gene; 2014 Aug; 546(1):63-7. PubMed ID: 24853201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
